The drug regulatory of India on Sunday announced its approval for the COVID-19 vaccines developed by Serum India and Bharat Biotech.
The approval for the use of these vaccines is, however, only for restricted use in an emergency situation.
The Subject Expert Committee of Central Drugs Standard Control Organization (CDSCO) met on January 1 and 2, 2021, and made recommendations in respect of a proposal for Restricted Emergency Approval of COVID-19 vaccine of M/s Serum Institute of India (SII) and M/s Bharat Biotech as well as Phase Three clinical trial of M/s Cadila Healthcare Ltd.
The Drugs Controller General of India (DCGI) stated that the vaccines developed by Serum Institute and Bharat Biotech have to be taken in two doses.
Prime Minister Narendra Modi took to Twitter to congratulate the two medical firms and also the scientists who worked on the two vaccines.
“A decisive turning point to strengthen a spirited fight!
DCGI granting approval to vaccines of @SerumInstIndia and @BharatBiotech accelerates the road to a healthier and COVID-free nation.
Congratulations India.
Congratulations to our hardworking scientists and innovators.” PM Modi wrote.
A decisive turning point to strengthen a spirited fight!
DCGI granting approval to vaccines of @SerumInstIndia and @BharatBiotech accelerates the road to a healthier and COVID-free nation.
Congratulations India.
Congratulations to our hardworking scientists and innovators.
— Narendra Modi (@narendramodi) January 3, 2021
Also Read: “Aakuali Care” An Innovative Initiative for Senior Citizens of Assam
